Numinus Bioscience is a global leader in supporting and expanding the safe, accessible, and evidence-based use of psychedelic-assisted psychotherapies (PAP). Operating a state-of-the-art research facility in British Columbia, Canada, Numinus Bioscience holds a Controlled Drugs and Substances license issued by Health Canada to allow the possession, production, assembly, sale, export, and delivery for a wide variety of psychedelic compounds and natural source materials, including Psilocybe mushroom fruiting bodies and extracts, Psilocybin, Psilocin, Ketamine, LSD, DMT, Mescaline and DMT. We are establishing ourselves at the forefront of analytical testing for psychedelics, as a center of excellence for product research and development, and as a supporting arm for psychedelic therapy clinical trials. If you would like to inquire about our lab testing and contract research services, please email us at laboratory-enquiries@numinus.ca.